Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively. 
 Total amortization expense was $19,500 and $61,000 for the three months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, estimated future amortization expense related to intangible assets is $51,000 for the remainder of the fiscal year ending, June 30, 2020, $54,300 for fiscal 2021, $31,700 for fiscal 2022, $15,000 for fiscal 2023 and $10,900 for fiscal 2024. 
 Approximately 36% and 49% of net sales of Benchtop Laboratory Equipment for the three month periods ended September 30, 2019 and 2018, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories. 
 The following table summarizes the Company’s disaggregation of revenues for the three months ended September 30, 2019 and 2018. 
 See notes to unaudited condensed consolidated financial statements. 
 See notes to unaudited condensed consolidated financial statements. 
 See notes to unaudited condensed consolidated financial statements. 
 See notes to unaudited condensed consolidated financial statements. 
 The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”). In accordance with Topic 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer. 
  The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through February 2025, a facility in Pittsburgh, Pennsylvania for its Catalyst Research Instrument Operations through November 2020 and another facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through November 2020. In addition, the Company had a lease for its Torbal Division of the Benchtop Laboratory Equipment Operations which was mutually terminated early effective as of October 31, 2019 and a new lease for a similar sales and administration office was entered into as of November 1, 2019 through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.  
 The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated. 
  The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.   Selling expenses for the three months ended September 30, 2019 increased $73,000 (30.9%) to $309,100 from $236,100 for the three months ended September 30, 2018 primarily due to increased market research and marketing activities by the Bioprocessing Systems Operations, and to a lesser extent increased marketing by the Benchtop Laboratory Equipment Operations. 
 Research and development expenses increased by $119,200 (101.5%) to $236,600 for the three months ended September 30, 2019 compared to $117,400 for the three months ended September 30, 2018, mainly due to the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing and materials. 
  Results of Operations. Net revenues for the three months ended September 30, 2019 decreased $34,400 (1.7%) to $2,004,200 from $2,038,600 for the three months ended September 30, 2018, reflecting a decrease of $115,700 (6.8%) decrease in net sales of Benchtop Laboratory Equipment primarily due to sales of its Genie brand products to Asia, particularly China. The Benchtop Laboratory Equipment sales reflected $522,400 of Torbal brand product sales for the three months ended September 30, 2019, compared to $425,300 in the three months ended September 30, 2018 as a result of continued growth in sales of the new force gauges product line. Sales of Catalyst Research Instruments decreased by $78,800 to $138,700 for the three months ended September 30, 2019 compared to $217,500 for the three months ended September 30, 2018 due to low order input during the period. As of September 30, 2019, the order backlog for Catalyst Research Instruments was $173,500, all of which is expected to be shipped during the fiscal year ending June 30, 2020, compared to $329,400 as of September 30, 2018. Revenues derived from the Bioprocessing Systems Operations which are comprised primarily of net royalties accrued from sublicenses increased by $160,100 (123.9%) to $289,300 for the three months ended September 30, 2019 compared to $129,200 for the three months ended September 30, 2018 due to increased royalties on Europe sales. 
 General and administrative expenses for the three months ended September 30, 2019 increased by $93,700 (22.5%) to $510,200 compared to $416,500 for the three months ended September 30, 2018 mainly due to the ramp up in Scientific Bioprocessing Operations, and various other corporate expenses. 
  Net cash used in operating activities was $324,100 for the three months ended September 30, 2019 compared to net cash provided by operating activities of $460,700 during the three months ended September 30, 2018, primarily as a result of the loss incurred for the current year period. Net cash used in investing activities was $25,700 for the three months ended September 30, 2019 compared to $4,900 used during the three months ended September 30, 2018 principally due to new capital equipment purchased during the current period by the Benchtop Laboratory Equipment Operations. The Company received proceeds of $7,000 in financing activities in the three months ended September 30, 2019 compared to a loss of $1,600 in the three months ended September 30, 2018 due to the exercise of stock options in the current year. 